Mutational landscape and risk estimates of DDR genes in Chinese ovarian cancer patients

Read full text
Authors: Cuiyun Zhang, Bing Wei, Xia Xue, Qingxin Xia, Yi Wang, Lanwei Guo, Tingjie Wang, L. WANG, Junli Deng, Yuping Guan, Xiaoyan Wang, Lu Feng
+6 more Rui Wu, Ziqing Hu, Klaas Kok, Anke van den Berg, Yongjun Guo, Jun Li
Cited by: 0

Abstract

Abstract Background Pathogenic/likely pathogenic variants (P/LPVs) in DNA damage response (DDR) genes are known ovarian cancer (OC) risk factors, but gene-specific risk estimates in Han Chinese remain unclear. Objective To accurately assess the risk associated with DDR genes in the Han Chinese population to facilitate personalized risk management and enhance clinical decision-making. Methods We performed next-generation sequencing of 45 DDR genes in 666 OC patients from Henan, China. Associations between P/LPVs and clinical features were assessed using chi-squared tests. Variant frequencies were compared with population controls (gnomAD and ChinaMAP databases) to estimate gene-specific odds ratios (ORs) using Fisher’s test. Results In Henan Ovarian Cancer patients, the median disease onset age was 53 years (range: 24–81), with 7.7% diagnosed before 40. Most patients had advanced disease (56.5% Stage III, 18.9% Stage IV), and 75.8% had high-grade serous carcinoma (HGSC). P/LPVs in BRCA1/2 were significantly associated with the HGSC subtype and a positive family history (p < 0.001 for both). Beyond BRCA1 (OR = 125.5/146.1) and BRCA2 (OR = 17.9/20.2), significantly elevated ovarian cancer risks were observed for RAD51D, RAD51C, and MSH2 (OR: 10.1–35.4, all p < 0.05). Conclusions This study provides the first gene-specific ovarian cancer risk estimates for DDR genes in Han Chinese, expanding the high-risk gene spectrum. By defining population-specific risk magnitudes, our findings provide a framework for clinical risk stratification, and underscore the need to tailor screening and prevention strategies to China’s distinct genetic landscape.

Fields of Study & Subjects

BRCA gene mutations in cancer Ovarian cancer diagnosis and treatment PARP inhibition in cancer therapy

Publication details

Journal / source
Figshare
Publication date
1 January 2026